 Q BioMed Inc told investors that it had studiously avoided biotech single-asset risks by acquiring multiple assets over time, across a broad spectrum of indications in large markets and its strategy was paying dividends. The New York-based company has a winner in cancer bone pain drug Strontium89 and a deep pipeline of biomedical assets. 